New Folate-Modified Human Serum Albumin Conjugated to Cationic Lipid Carriers for Dual Targeting of Mitoxantrone against Breast Cancer

• Published in: Current pharmaceutical biotechnology Vol. 21; no. 4; p. 305
• Main Authors: Ridha, Abbas A, Kashanian, Soheila, Azandaryani, Abbas H, Rafipour, Ronak, Mahdavian, Elahe
• Format: Journal Article
• Language: English
• Published: Netherlands 01.01.2020
• Subjects: Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacology; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Cations; Cell Line, Tumor; Cell Survival - drug effects; Drug Carriers - chemistry; Drug Liberation; Folic Acid - chemistry; Humans; Lipids - chemistry; MCF-7 Cells; Mitoxantrone - administration & dosage; Mitoxantrone - pharmacology; Nanoparticles - chemistry; Particle Size; Serum Albumin, Human - chemistry; TPLNs; Mitoxantrone; folic acid; dual drug targeting; human serum albumin; cationic solid lipid nanoparticle

In the present work, folic acid-modified human serum albumin conjugated to cationic solid lipid nanoparticles were synthesized as nanocarriers of mitoxantrone for the treatment of breast cancer. Dual-targeted drug delivery is a new drug dosing strategy that is frequently used to enhance the therapeu...